Thermo Fisher Scientific and AstraZeneca to Co-Develop NGS-based Companion Diagnostics

Thermo Fisher Scientific and AstraZeneca to Co-Develop NGS-based Companion Diagnostics CARLSBAD, Calif., Sept. 1, 2021 /PRNewswire/ — Thermo Fisher Scientific’s clinical sequencing business and AstraZeneca today announced they will co-develop next-generation sequencing (NGS)-based companion diagnostics (CDx) to support AstraZeneca’s expanding portfolio of targeted therapies. The companies will collaborate under a multiyear, global agreement. “As the... Read more

FDA Approves NGS-Based Companion Diagnostic for Previously Treated IDH1-Mutated Cholangiocarcinoma

FDA Approves NGS-Based Companion Diagnostic for Previously Treated IDH1-Mutated Cholangiocarcinoma CDx approval expands clinical utility of Oncomine Dx Target Test to identify candidates for TIBSOVO CARLSBAD, Calif., Aug. 25, 2021 /PRNewswire/ — The U.S. Food and Drug Administration (FDA) has granted pre-market approval to Thermo Fisher Scientific’s Oncomine Dx Target Test as a companion diagnostic (CDx) to... Read more

GE Healthcare Brings Radiology Without Walls to Resource-Constrained Small Imaging Centers With AI-Enabled, Cloud Imaging Solution

GE Healthcare Brings Radiology Without Walls to Resource-Constrained Small Imaging Centers With AI-Enabled, Cloud Imaging Solution ·       Edison True PACS[1] is a transformative system, offering AI-enabled decision support to help radiologists adapt to higher workloads and increased exam complexity, and improve diagnostic accuracy ·       Innovative, cloud-based system removes barriers to adopting new diagnostic radiology efficiency... Read more

Agilent Announces Target Enrichment Manufacturing Facility in China

Customers will benefit from reduced delivery time for next generation sequencing (NGS) products  SANTA CLARA, Calif., August 03, 2021  Agilent Technologies Inc. (NYSE: A) today announced that it has established in-country manufacturing for its SureSelect portfolio at its facility in Hangzhou, China. Agilent is a leading provider of next-generation sequencing assays, and customers often develop... Read more

Rigaku Acquires Life Science Imaging Equipment Manufacturer MILabs

Full-Scale Entry into the Global Life Sciences Business Rigaku Corporation (Headquarters: Akishima-shi, Tokyo; President: Toshiyuki Ikeda; “Rigaku”), a leading manufacturer of X-ray analysis equipment, has acquired all issued shares of MILabs B.V. (Headquarters: Houten, The Netherlands; CEO and CSO: Dr. Frederik Beekman; “MILabs”) on August 2, 2021, as part of their full-scale effort to enter... Read more

Abcam to acquire BioVision for $340 million

2 August 2021, Cambridge, UK  – Abcam plc (“Abcam”, “the Company” or “the Group”) (AIM LSE: ABC; Nasdaq: ABCM), a global leader in the supply of life science research tools, announces that it has entered into a definitive agreement to acquire BioVision, Inc. (“BioVision”), a wholly owned subsidiary of Boai NKY Medical Holdings Ltd. (“NKY”), for... Read more

10x Genomics Signs Global Patent Cross License Agreement with Bio-Rad

July 27, 2021 at 6:30 AM EDTPDF Version Agreement to Cross License Single Cell Technologies Ends all Ongoing Legal Disputes  PLEASANTON, Calif., July 27, 2021 (GLOBE NEWSWIRE) — 10x Genomics, Inc. (Nasdaq: TXG) today announced that it has entered into a global settlement and cross-license agreement with Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb). The... Read more

PerkinElmer’s COVID-19 RT-PCR Test Kit Receives FDA Emergency Use Authorization for Saliva as Specimen Type

Non-invasive sampling method makes it easier to use the highly sensitive molecular test manufactured by PerkinElmer WHAT: PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced that the U.S. Food and Drug Administration (FDA) has authorized the PerkinElmer® New Coronavirus Nucleic Acid Detection Kit for an additional indication that permits... Read more

Bruker Announces Date and Time of Second Quarter 2021 Earnings Release and Webcast

BILLERICA, Mass.–(BUSINESS WIRE)– Bruker Corporation (Nasdaq: BRKR) today announced it will report second quarter 2021 financial results on Monday, August 2, 2021, after the market closes. The Company will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the results and current business trends. To listen to the webcast, investors can... Read more